Crowd sentiment on MYGN · 30d

Method · 0 mentions

Bullish 0%

Neutral 100%

Bearish 0%

Across 0 classified mentions in the last 30 days, crowd sentiment for MYGN sits roughly neutral, with 0% reading bullish against 0% bearish across the classified sample.

MYGN insider trades

SEC Form 4

Date Insider Type Shares Value

11 Jun 2026 Donnelly Brian J Chief Commerical Officer AWARD 5,000 $20K

11 Jun 2026 Raha Samraat S. President and CEO AWARD 3,542 $14K

08 Jun 2026 Kumar Rashmi Director SELL 15,000 $67K

04 Jun 2026 Bisaro Paul Director AWARD 59,701 —

04 Jun 2026 Davis Mark Steven Director AWARD 59,701 —

04 Jun 2026 Dreismann Heinrich Director AWARD 59,701 —

04 Jun 2026 Kumar Rashmi Director AWARD 59,701 —

04 Jun 2026 Phanstiel S. Louise Director AWARD 59,701 —

MYGN earnings

SEC EDGAR

Date Period EPS Revenue

31 Mar 2026 Q1 2026 $-0.36 —

31 Dec 2025 FY 2025 $-3.95 —

30 Sep 2025 Q3 2025 $-0.29 —

30 Jun 2025 Q2 2025 $-3.57 —

Reported figures & scheduled dates · SEC EDGAR filings

About MYGN

Myriad Genetics develops and sells molecular diagnostic tests that analyze genes and gene expression to assess disease risk, disease progression, and treatment response. The company offers tests in areas such as cancer, prenatal health, and mental health, including hereditary cancer testing and cancer therapy selection. Myriad has entered into collaborations with PATHOMIQ, Inc. and SOPHiA GENETICS S.A. to enhance its oncology portfolio and develop new diagnostic solutions. In 2025, the company transitioned its laboratory operations to new facilities designed for greater automation and efficiency.

Company

CEO Mr. Samraat S. Raha

Founded 1992

Employees 2,700

Headquarters Salt Lake City, UT, United States

Exchange NasdaqGS

Sector Healthcare

Class Equity

Mentions · 30d 0

Classified base n=0

Website myriad.com

Most-discussed this week

GOOGL Alphabet MSFT Microsoft NFLX Netflix NVDA NVIDIA